Literature DB >> 29372598

Risk of hospitalization associated with anticholinergic medication for patients with dementia.

Shuichi Watanabe1, Takahide Fukatsu1, Kosuke Kanemoto1.   

Abstract

BACKGROUND: With the ageing of the general population, demand has grown for measures to prevent hospitalization for dementia, which can exacerbate problems associated with activities of daily living in elderly individuals. Anticholinergic medication has been shown to cause falls, delirium, and cognitive impairment in aged patients. However, the risk of hospitalization associated with the administration of anticholinergics is unclear.
METHODS: We analyzed the records of 61 outpatients (26 men, 35 women; mean age: 78 ± 7 years; mean follow-up period: 420 days) diagnosed with dementia (Alzheimer's disease: n = 45; dementia with Lewy bodies: n = 3; undifferentiated n = 13) and prescribed anti-dementia drugs between May 2013 and December 2014. Medication history was noted, and the patients were divided into two groups according to the Anticholinergic Risk Scale: with risk (n = 13) and without risk (n = 48). Outcome was judged based on an end-point of hospitalization or death. Kaplan-Meier survival and Cox proportional hazard analyses were performed.
RESULTS: Eight patients with anticholinergic risk and 12 without anticholinergic risk reached the end-point (P < 0.005). Analysis with a proportional hazard model showed that anticholinergic medication administration was related to a higher risk for reaching the end-point (crude hazard ratio: 3.62, 95% confidence interval: 1.45-9.04, P < 0.01; adjusted hazard ratio: 4.54, 95% confidence interval: 1.03-20.0, P < 0.05). In contrast, Mini-Mental State Examination score, Charlson Comorbidity Index, and the number of drugs were not major risk factors for hospitalization in patients with dementia.
CONCLUSION: The Anticholinergic Risk Scale findings were shown to be a strong predictor of hospitalization for patients with dementia. We should evaluate the anticholinergic burden before initiating anti-dementia therapy.
© 2018 Japanese Psychogeriatric Society.

Entities:  

Keywords:  adverse effect; antidepressants; antipsychotics; dementia; risk factors

Mesh:

Substances:

Year:  2018        PMID: 29372598     DOI: 10.1111/psyg.12291

Source DB:  PubMed          Journal:  Psychogeriatrics        ISSN: 1346-3500            Impact factor:   2.440


  2 in total

1.  Development of an Emergency Revisit Score for Patients With Drug-Related Problems.

Authors:  Jesus Ruiz Ramos; Laura Gras-Martin; Ana María Juanes Borrego; Marta Blazquez-Andion; Mireia Puig Campmany; Maria Antonia Mangues-Bafalluy
Journal:  J Pharm Technol       Date:  2021-04-30

Review 2.  The role of sex, age and genetic polymorphisms of CYP enzymes on the pharmacokinetics of anticholinergic drugs.

Authors:  Shanna C Trenaman; Susan K Bowles; Melissa K Andrew; Kerry Goralski
Journal:  Pharmacol Res Perspect       Date:  2021-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.